- All
- Product Management
- News
- Introduction
- Enterprise outlets
- FAQ
- Enterprise Video
- Enterprise Atlas
The second phase of the production base of Chuangyuan Biotechnology and the key laboratory for micro-ecological preparations has reached its topping-out.
On October 5, 2022, the biomedical industry in the Binhai High-tech Zone received good news, as Tianjin Chuangyuan Biotechnology Co., Ltd. completed the topping out of thePhase II production base and key laboratory for micro-ecological preparations.The project started construction on May 12, 2022, and is expected to be completed in December this year. Once completed, it will become an important base for the company's R&D and production, adding new support for the construction of the Beijing-Tianjin-Hebei characteristic cell valley in the high-tech zone.
Walking into the construction site located at the intersection of Kangtai Avenue and Gaoxin No. 1 Road in the Binhai High-tech Zone, workers are racing against time to catch up on construction progress, and the construction atmosphere is intense. According to reports, the Phase II production base and key laboratory for micro-ecological preparations of Chuangyuan Biotechnology has a building area of approximately 25,105 square meters, including an office building with a footprint of 970.96 square meters, a building area of 2,994.58 square meters, and a building height of 14.31 meters; Factory No. 1 has a footprint of 927.36 square meters and a building area of 2,993.72 square meters; Factory No. 2 has a footprint of 927.36 square meters and a building area of 2,785.34 square meters; the joint factory has a footprint of 16,048 square meters and a building area of 16,283.50 square meters.
Tianjin Chuangyuan Biotechnology Co., Ltd. was established in 2018 and is a Sino-American joint venture national high-tech enterprise. It has a research and development center focused on various probiotic segmented solid-state fermentation technologies and process research, as well as modern preparation production workshops. At the same time, it closely collaborates with several well-known universities and authoritative research institutions both domestically and internationally, including Tianjin University of Science and Technology, Harvard University, National University of Singapore, Tsinghua University Shenzhen Research Institute, and the National Key Laboratory of Food Nutrition and Safety co-built with provincial and ministerial departments, to jointly build R&D platforms. According to relevant data,Chuangyuan Biotechnologyhas more than 40 patents and has established its own functional probiotic bank, preserving over 3,000 strains of probiotics, with 16 core specialized strains stored at the Institute of Microbiology, Chinese Academy of Sciences. Currently, the company has developed and launched various health foods rich in probiotics, prebiotics, and postbiotics.health foods, and is at an internationally advanced level in various probiotic segmented solid-state fermentation technology fields.
A relevant person in charge of Chuangyuan Biotechnology stated that after the completion of the Phase II production base and key laboratory for micro-ecological preparations, it will rely on the R&D platform co-built with well-known domestic and foreign universities, focusing on the innovation of various probiotic segmented solid-state fermentation technologies, accelerating the development process of small molecular active substances and drugs produced by intestinal microbial cells, continuously and deeply carrying out product R&D and production, expanding production capacity and national marketing layout. It is expected to achieve an annual operating income of over 1 billion yuan and pay over 100 million yuan in taxes within five years. While building itself into a world-class biotechnology enterprise, it will also contribute to the construction of the cell valley in the Binhai High-tech Zone and promote the development of Tianjin's health industry.
Chuangyuan Biotechnology, health food, probiotics, Phase II project, Tianjin Chuangyuan Biotechnology Co., Ltd.
Related News



